Earnings season isn’t over yet. There are still plenty of publicly traded companies that have yet to come out with their quarterly financial updates, and that list includes several of the more controversial names to go public in 2019…
Author: admin
Surprise! Billionaire Money Managers Bought These Pot Stocks in the Fourth Quarter
As you’re probably aware, marijuana stocks had an awful 2019. Though last year was supposed to be when cannabis stocks proved to Wall Street that they deserved premium valuations, supply issues in Canada and high tax rates in select U.S.…
3 Marijuana Stocks That Rode Canopy Growth’s Q3 Earnings Coattails and Could Rise Even Higher
When a major player in a given industry performs really well, it can often set the stage for the shares of others in the same industry to rise also. This is called a sympathy play. And it just happened in…
4 Reasons Why We Could See a Turnaround in Aurora Cannabis (ACB)
It’s been a tough couple of years for Aurora Cannabis (ACB) investors. The stock has fallen over 85%, from all-time highs hit in 2018, to trade just at about $1.65 on the NYSE. In addition to industry wide challenges, such…
Which 4 Marijuana Stocks Could Soon Face Delisting
Last year was expected to be when marijuana stocks proved their worth to Wall Street. Unfortunately, that’s not what happened, and investors suffered through the worst year on record for cannabis stocks. To our north, regulatory-based supply problems have wreaked havoc…
Donald Trump and Marijuana: Everything You Need to Know
Whether you’re ready for it or not, election season is now in full swing. Roughly a dozen candidates still remain in the field to become president, including incumbent Republican Donald Trump, and quite a few Democratic contenders. While there are…
Why Canopy Growth Stock Is Skyrocketing Today
Shares of Canopy Growth (NYSE:CGC) rose sharply on Friday morning after the company announced its fiscal 2020 third-quarter results. The Canadian cannabis producer reported net revenue of 123.8 million Canadian dollars, up 49% year over year and 62% quarter over quarter. That…
4 Pot Stocks Capable of $1 Billion in Annual Sales by 2022
Last year was supposed to be when marijuana stocks proved their worth to Wall Street. Following years of promises, and plenty of acquisition activity, it was widely believed that sales would soar and pot stocks would push into the profit…
What to Expect From Canopy Growth When it Reports Earnings on Friday
As the cannabis sector continues to push forward, or should we say fall down, earnings season has arrived once again. So far, we have seen mid-cap licensed producers, like Aphria and OrganiGram, report decent earnings. Next up is Canopy Growth (CGC), which…
Is GW Pharmaceuticals Stock a Buy?
GW Pharmaceuticals (NASDAQ:GWPH) hit paydirt when its crown jewel — Epidiolex — became the first cannabidiol-derived drug approved by the U.S. Food and Drug Administration (FDA). Epidiolex is a treatment for seizures in patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, both…
